Y-90 Zevalin
Generic name: ibritumomab [ ib-ri-TYOO-mo-mab ]
Drug classes: CD20 monoclonal antibodies, Radiologic conjugating agents
What is Y-90 Zevalin?
Y-90 Zevalin is a protein that targets white blood cells in the body. When this medicine is attached to a radioactive chemical, the radiation is delivered directly to the tumor (lymphoma).
Y-90 Zevalin is used in combination with other medicines to treat non-Hodgkin's lymphoma.
Y-90 Zevalin may also be used for purposes not listed in this medication guide.
Y-90 Zevalin side effects
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Life-threatening reactions may occur during the injection or within 24 hours afterward. Tell your caregivers or seek medical attention if you feel light-headed or short of breath, or if you have chest tightness or pain spreading to your jaw or shoulder.
Serious and sometimes fatal infections or skin reactions may occur during treatment with Y-90 Zevalin, and up to 4 months afterward. Call your doctor right away if you have:
-
redness, ulcers, or skin changes where the medicine was injected;
-
easy bruising, unusual bleeding, purple or red spots under your skin;
-
unusual weakness or tiredness;
-
low red blood cells (anemia)--pale skin, weakness, cold hands and feet; or
-
low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing.
Common side effects of Y-90 Zevalin may include:
-
nausea, stomach pain, diarrhea;
-
fever, cough;
-
stuffy nose, sore throat, sinus pain; or
-
feeling weak or tired.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Warnings
Life-threatening reactions may occur during the injection or within 24 hours afterward. Tell your caregivers or seek medical attention if you feel light-headed or short of breath, or if you have chest tightness or pain spreading to your jaw or shoulder.
Serious and sometimes fatal infections or skin reactions may occur during treatment with Y-90 Zevalin, and up to 4 months afterward. Call your doctor right away if you have: fever, chills, mouth sores, pale skin, cold hands and feet, feeling light-headed or short of breath, easy bruising or bleeding, or skin changes where the medicine was injected.
Before taking this medicine
You should not be treated with Y-90 Zevalin if you are allergic to Y-90 Zevalin, or to radioactive chemicals or mouse proteins.
Tell your doctor if you have ever had:
-
any type of infection;
-
bleeding or blood clotting problems;
-
breathing problems; or
-
if you take a blood thinner (warfarin, Coumadin) or other medicine to prevent blood clots.
Using Y-90 Zevalin may increase your risk of developing other types of cancer, such as leukemia or preleukemia. Ask your doctor about your specific risk.
You may need to have a negative pregnancy test before starting this treatment.
Both men and women using this medicine should use effective birth control to prevent pregnancy. Y-90 Zevalin can harm an unborn baby or cause birth defects if the mother or father is using this medicine. Keep using birth control for at least 12 months after your last dose.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using Y-90 Zevalin.
Do not breastfeed while using this medicine, and for at least 6 months after your last dose.
How is Y-90 Zevalin given?
Y-90 Zevalin is used in combination with rituximab (Rituxan) and a radioactive chemical. This medicine is given as an infusion into a vein. A healthcare provider will give you this injection.
Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when Y-90 Zevalin is injected.
You may be given medicine to prevent certain side effects while you are receiving Y-90 Zevalin. Take all of the medicines your doctor has prescribed.
Y-90 Zevalin can increase your risk of bleeding or infection. You will need frequent medical tests.
Related/similar drugs
methotrexate, rituximab, cyclophosphamide, Rituxan, vincristine, Cytoxan
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your Y-90 Zevalin.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while receiving Y-90 Zevalin?
Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.
Do not receive a "live" vaccine while using Y-90 Zevalin, and for at least 12 months after your treatment ends. The vaccine may not work as well during this time, and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.
What other drugs will affect Y-90 Zevalin?
Other drugs may affect Y-90 Zevalin, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Y-90 zevalin Biosimilars
Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.
Reference products
These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Y-90 Zevalin.
Zevalin (ibritumomab tiuxetan) - Acrotech Biopharma Inc.
Formulation type | Strength |
---|---|
Single-Dose Vial | 3.2 mg/2 mL |
View Zevalin information in detail.
More about Y-90 Zevalin (ibritumomab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: CD20 monoclonal antibodies
- En español
Patient resources
Other brands
Professional resources
Other formulations
Related treatment guides
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2024 Cerner Multum, Inc. Version: 5.02.